New drug hope for cystic fibrosis patients

Sep 09, 2008

A new drug therapy may represent a tremendous step forward in the treatment of some 70,000 cystic fibrosis (CF) patients worldwide, Dr David Sheppard from the University of Bristol will tell an audience at the BA Festival of Science in Liverpool tomorrow.

Speaking ahead of the conference, Dr Sheppard said: 'The early results with VX-770 suggest that drug therapies which target defects at the root of the disease have the potential to improve greatly the quality of life of CF patients.'

At the moment there is no cure for CF – a common single-gene disorder in the UK. The disease, which affects about 8,000 people in the UK and 70,000 people worldwide, is due to a defective gene that causes ducts and tubes in the body to become blocked by thick, sticky mucus. This mucus affects the lungs, pancreas, the intestines, the liver and the reproductive organs.

One of the most recognisable symptoms of CF is 'salty sweat', caused by the failure of the sweat ducts to reabsorb salt. Existing treatments only alleviate symptoms, for example, physiotherapy to clear the air passages, antibiotics for lung infections and enzymes to aid the digestion of food.

The defective gene disables or destroys a protein known as CFTR. To date around 1,500 genetic defects have been found in this protein. In general, genetic defects cause harm in two ways – some stop the protein from travelling to its correct destination in cells, whereas others prevent the protein from working properly.

Dr Sheppard's research group, supported by the Cystic Fibrosis Trust, investigates how new drugs restore function to defective CFTR proteins and EuroCareCF, of which Dr Sheppard is the coordinator, works to promote CF therapy development in Europe.

The new drug therapy (VX-770) was developed by Vertex Pharmaceuticals and will tackle the 'functional' defect. It has been tested on CF patients in the US who carry a genetic defect known as G551D. European trials are expected in the future. Early results are very encouraging. Patients who received 150mg twice a day saw the concentration of salt in their sweat decrease by almost 50 per cent and lung function improve by 10 per cent.

The Cystic Fibrosis Foundation funded the discovery and early development work of VX-770 in collaboration with Vertex Pharmaceuticals. To date the Foundation has invested $79 million in the project. Results of the trials can be found here. Dr Sheppard's research group and other academic groups and companies are also working to develop new drugs that tackle defects at the root of CF.

Current life expectancy for CF patients is between 30 and 40 years of age in Western Europe and the US but is considerably lower in other parts of the world. One in 25 people in the UK is a carrier of a defective CF gene, making CF one of the most common life-shortening, childhood-onset, inherited diseases.

Source: University of Bristol

Explore further: Solid, heat-resistant vaccine to ease immunisation processes

Related Stories

High fidelity: Researcher finds keys to genome integrity

Apr 14, 2015

Maintaining the stability and the correct sequence of our genetic information is vital to the accurate transmission of our genetic code. However, in the course of replicating, our DNA frequently runs into ...

Gold nanoparticles for targeted cancer treatment

Mar 26, 2015

The use of tiny drug-loaded nanocarriers for the safe, targeted delivery of drugs to designated parts of the body has received much press in recent years. Human trials of nanocarriers targeting pancreatic ...

Recommended for you

Solid, heat-resistant vaccine to ease immunisation processes

Apr 30, 2015

EU researchers have set out to substitute liquid and freeze-dried vaccines for new, solid state candidates. If successful, the research will enable the large scale production of new virosome-based vaccines with increased ...

Screening for bacteriuria in pregnant women: Benefit unclear

Apr 30, 2015

Due to a lack of suitable studies, no conclusions can be drawn on the patient-relevant benefit or harm of screening for asymptomatic bacteriuria (ASB) in pregnant women. The benefit of antibiotic treatment of ASB following ...

First generic Abilify approved

Apr 30, 2015

(HealthDay)—The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.